Stiff Person Syndrome
New stiff person syndrome research, summarized each month in plain language.
2026 so far: So far in 2026 (January 2026 to September 2026), real-world reports focused on immune therapies and intrathecal baclofen pumps for severe symptoms, while observational studies added detail on long-term disability and mortality risk. Read the 2026 review
We also cover clinical trials.
Yearly update
2026 so far
- Baclofen pumps and symptom drugs. Small series highlighted pump benefits alongside meaningful procedure risks.
- Immune treatment combinations. Case-level reports increasingly described sequential or combined immunotherapies.
- Long-term outcomes. Observational studies sharpened the picture of disability and survival.
- Testing and diagnosis. Reports reinforced antibody-led workups and highlighted limits of single tests.
- Cancer links and complications. Evidence highlighted a cancer-linked antibody subgroup and rare ICU-level events.
New
September 2026
- Tube removal spasms. Severe spasms during tube removal were followed by low oxygen.
- Dangerous heart rhythm. A life-threatening heart rhythm occurred after the episode.
- Unclear heart cause. MRI suggested heart inflammation, but it was not confirmed.
August 2026
- Baclofen pump effects. A small report linked pumps to less stiffness, with infection risk.
- GABA-targeting drugs. Some people improved after clonazepam, with or without baclofen.
- Anti-amphiphysin cancers. Anti-amphiphysin SPS was often tied to cancers found later.
July 2026
- Immune treatment reports. Some severe cases improved, but the main drug was unclear.
- Autoimmune overlap. About half had another autoimmune condition, often diabetes.
- EMG reflex limits. One surface EMG reflex test did not clearly separate SPS.
June 2026
- 10-year survival. One registry found higher 10-year mortality after SPS diagnosis.
- Diagnosis trends. In one country, SPS diagnoses increased over time.
- Seizure response. In anti-GAD65 disease, steroids or IVIG often reduced seizures.
May 2026
- Daily independence over time. In one long follow-up group, many people became more independent in daily activities over time.
- Ongoing walking limitations. Walking difficulty often continued, and many people still needed gait aids years later.
- Early immune signals (uncertain for SPS). Some studies reported HLA and blood immune patterns in anti-GAD65 neurologic disease, but it is not clear how well these findings apply to stiff person syndrome.
- SPS can resemble other conditions. Case reports showed that SPS may look like other disorders at first, until features such as trigger-induced spasms and anti-GAD65 antibodies provide clearer clues.
April 2026
- Anti-amphiphysin patterns. In a small set of anti-amphiphysin cases, symptoms were broader than stiffness and spasms, and some reports included possible cancer links.
- Medication-timed flare. One single-person report described symptom worsening after starting tandospirone, followed by improvement after immunotherapy.
- Glycine receptor binding sites. Lab mapping showed glycine receptor antibodies can attach to different parts of the receptor rather than one single site.
March 2026
- GAD65 autoimmunity beyond the nervous system. Reports linked stiff person syndrome to GAD65-related autoimmunity that can involve more than one organ system.
- Seizures or encephalitis with stiffness. Some reports described stiff person symptoms occurring together with seizures or brain inflammation.
- PET signal matched symptom areas. In GAD65 encephalitis, brain PET activity tended to appear in regions that matched a person’s main symptoms.
February 2026
- SPS can look orthopedic at first. Some reported SPS cases were first treated as orthopedic or other movement problems, and anti‑GAD antibodies were a repeated clue when routine tests did not clearly explain symptoms.
- SPS with other autoimmune conditions. In a small case series, SPS was described alongside Sjögren’s syndrome and other autoimmune diagnoses, and stiffness began years before dry eye and dry mouth symptoms in those reports.
- Lab model tests antibody effects. A 3D spinal cord neuron model showed patient‑derived SPS antibodies disrupting nerve network activity, but this research tool does not predict what will happen for any one person.
January 2026
- Anti-GAD65 testing. Anti-GAD65 antibody results were still used as part of confirming stiff person syndrome, with extra tests added in some complex presentations.
- EMG after diazepam. In one person, needle EMG findings changed after an intravenous diazepam challenge in a way that matched symptom change, showing one method to document abnormal muscle activity.
- Sleep symptoms in SPS. One case highlighted sleep paralysis and marked daytime sleepiness as major problems, and sleep testing did not support obstructive sleep apnea or narcolepsy as the cause.
Get the monthly update by email
Subscribe here to receive an email when a new monthly stiff person syndrome update is published. You can unsubscribe at any time. Your address is used for this only; delivery is handled by MailerLite (privacy policy).